Evidence map›Paper›PMID 37376574›Full record

ArticleViruses2023

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose.

Guillaume Beaudoin-Bussières, Alexandra Tauzin, Katrina Dionne, Gabrielle Gendron-Lepage, Halima Medjahed, Josée Perreault, Inès Levade, Laila Alfadhli, Yuxia Bo, Renée Bazin and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Alexandra TauzinCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.ORCID 0000-0001-9153-3600
Katrina DionneCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Gabrielle Gendron-LepageCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Josée PerreaultHéma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
Inès LevadeLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.ORCID 0000-0003-3488-7255
Laila AlfadhliDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Yuxia BoDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Renée BazinHéma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.ORCID 0000-0001-9594-2532
Marceline CôtéDepartment of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0002-4664-4325
Andrés FinziCentre de Recherche du CHUM, Montréal, QC H2X 0A9, Canada.
Centre Hospitalier de l’Université de Montréal · CAUniversity of Ottawa · CAHéma-Québec · CAInstitut National de Santé Publique du Québec · CA

Funding

CIHR
6 · The paper itself

Abstract

Since the beginning of the SARS-CoV-2 pandemic, several variants of concern (VOCs), such as the Alpha, Beta, Gamma, Delta and Omicron variants, have arisen and spread worldwide. Today, the predominant circulating subvariants are sublineages of the Omicron variant, which have more than 30 mutations in their Spike glycoprotein compared to the ancestral strain. The Omicron subvariants were significantly less recognized and neutralized by antibodies from vaccinated individuals. This resulted in a surge in the number of infections, and booster shots were recommended to improve responses against these variants. While most studies mainly measured the neutralizing activity against variants, we and others previously reported that Fc-effector functions, including antibody-dependent cellular cytotoxicity (ADCC), play an important role in humoral responses against SARS-CoV-2. In this study, we analyzed Spike recognition and ADCC activity against several Omicron subvariants by generating cell lines expressing different Omicron subvariant Spikes. We tested these responses in a cohort of donors, who were recently infected or not, before and after a fourth dose of mRNA vaccine. We showed that ADCC activity is less affected than neutralization by the antigenic shift of the tested Omicron subvariant Spikes. Moreover, we found that individuals with a history of recent infection have higher antibody binding and ADCC activity against all Omicron subvariants than people who were not recently infected. With an increase in the number of reinfections, this study helps better understand Fc-effector responses in the context of hybrid immunity.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralAntibody-Dependent Cell CytotoxicityHumansmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ADCCcoronavirusCOVID-19Fc-effector responseshybrid immunityomicronSARS-CoV-2spike glycoproteinsvariants of concern

Identifiers

PMID37376574
PMCPMC10302413
OpenAlexW4380143017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.